NCT03251443View on ClinicalTrials.gov

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 8, 2017

Primary Completion Date

March 8, 2019

Study Completion Date

May 8, 2019

Conditions
Intrahepatic CholangiocarcinomaSecond-line Treatment
Interventions
DRUG

Apatinib

500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT03251443 - A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma | Biotech Hunter | Biotech Hunter